vutrisiran
Amvuttra

*Pharmaceutical company:* Alnylam Pharmaceuticals

*Pharmacologic classification:* Anti-transthyretin small interfering RNA agent

*Therapeutic classification:* Protein inhibitor

---

**AVAILABLE FORMS**

*Injection:* 25 mg/0.5 mL prefilled syringe

**INDICATIONS AND DOSAGES**

*Polyneuropathy of hereditary transthyretin-mediated amyloidosis*

*Adults:* 25 mg subcut every three months.

**CONTRAINDICATIONS AND CAUTIONS**

- This drug hasn’t been studied in those with severe renal impairment, end-stage renal disease, or moderate to severe hepatic impairment.
- Safety and effectiveness in children haven’t been established.
- *Dialyzable drug:* Unknown.

**PREGNANCY-LACTATION-REPRODUCTION**

- There are no available data on use during pregnancy. Use in pregnancy only if the benefit clearly outweighs the fetal risk.
- There is no information regarding the presence of this drug in human milk, the effects on the breastfed infant, or the effects on milk production. Use cautiously during breastfeeding.

**INTERACTIONS**

None reported.

**ADVERSE REACTIONS**

*CV: AV block.*

*Metabolic:* decreased vitamin A.

*Musculoskeletal:* arthralgia.

*Respiratory:* dyspnea.

*Skin:* injection site reactions (bruising, erythema, pain, pruritus, warmth).

*Other:* anti-drug antibody development.

Reactions in bold italics are *life-threatening.*

*Released: November 2022*